Clinical Trial

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-09-01; most recent amendment 2025-05-21.
Trial Details
NCT Number NCT05039866
Lead Sponsor Sangamo Therapeutics
Conditions Fabry Disease, Fabry Disease, Cardiac Variant
Enrollment 48 participants
Start Date 2021-08-16
Primary Completion 2029-03 (estimated)
Study Completion 2039-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-25